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Abstract 
Background: Duchénnè/Becker muscular dystrophies (DMD/BMD) are X-linked diseases, which 
are caused by a de novo gene mutation in one-third of affected males. The study objectives were to 
determine the incidence of DMD/BMD in Andalusia (Spain) and to establish the percentage of 
affected males in whom a de novo gene mutation was responsible.  
Methods: Multiplex ligation-dependent probe amplification (MLPA) technology was applied to 
determine the incidence of DMD/BMD in 84 males with suspicion of the disease and 106 female 
relatives.  
Results: Dystrophin gene exon deletion (89.5%) or duplication (10.5%) was detected in 38 of the 
84 males by MLPA technology; de novo mutations account for 4 (16.7%) of the 24 mother-son pairs 
studied. 
Conclusions: MLPA technology is adequate for the molecular diagnosis of DMD/BMD and es-
tablishes whether the mother carries the molecular alteration responsible for the disease, a highly 
relevant issue for genetic counseling. 
Key words: Duchénnè/Becker; Multiplex Ligation-dependent Probe Amplification (MLPA);  de 
novo mutations. 
Introduction 
Duchénnè and Becker muscular dystrophies 
(DMD/BMD) are the most frequent genetic diseases 
among dystrophinopathies, which are caused by al-
terations of the dystrophin protein, essential in the 
interaction between cytoskeletal muscle fibers and 
extracellular matrix; however, although DMD and 
BMD are caused by mutations in the same gene, they 
have different ages of onset and distinct severity lev-
els [1-3]. DMD is transmitted in a recessive X-linked 
fashion; the gene responsible  (dystrophin gene 
[DMD]) is located in the short arm of chromosome X 
at locus 21 (Xp21), has a size of 2.4 Mb, and is formed 
by 79 exons. This disease affects males, while females 
are carriers, although some of them can manifest 
symptoms that vary from mild muscle weakness to a 
more severe clinical course [1]. Carrier females are at 
50% risk of having an affected male or carrier female 
offspring.  
The reported incidence is 1:3500 live newborn 
males for DMD and 1:18000 for BMD [1-3]. The dis-
ease is characterized by progressive symmetrical 
muscle weakness, which is earlier and more severe in 
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DMD cases [2].  
There are 4,000 known variations of the DMD 
gene (http://www.dmd.nl), of which the most im-
portant involve: the deletion of one or more exons 
(65% for Duchénnè and 85% for Becker); duplication 
of one or more exons (5-10% for DMD/BMD); or point 
mutations, small deletions, or insertions (25-30% for 
DMD and 5-10% for BMD) [4-7]. The two exon areas 
with the highest probability of deletions (hotspots) are 
between exons 44 and 53 and between exons 2 and 20 
[4]. In 1935, Haldane reported that DMD/BMD is 
caused by sporadic mutations in one-third of the pa-
tients [8] and that this proportion depends on the pa-
tient’s sex [9]. It is crucial to determine whether a de 
novo  mutation or a mutation inherited from the 
mother is responsible for the disease, for which no 
effective treatment is available, in order to offer ap-
propriate genetic counseling to the family of each af-
fected male.  
It has been known since 1987 that most of the 
mutations that cause DMD/BMD are preferentially 
found in 18 gene regions [10]; however, studies of 
these regions using different methods (southern-blot, 
quantitative PCR, multiplex amplifiable probe hy-
bridization [MAPH], or fluorescent in situ hybridiza-
tion [FISH]) proved able to detect alterations in only 
20-30% of the 79 exons of the DMD gene [11-13]. The 
recently developed multiplex ligation-dependent 
probe amplification (MLPA) assay is a more useful 
technique for the study of index cases and possible 
carriers [14, 15], because it allows the detection of de-
letions and duplications of all exons of the gene [2, 13, 
16-18]. However, it is important to confirm single 
exon deletions because of the possibility of small 
mutations (single nucleotide polymorphisms [SNPs], 
point mutations) preventing MLPA probe amplifica-
tion [19]. 
The study objectives were to determine the in-
cidence of DMD/BMD in Andalusia (Spain) and to 
establish the percentage of affected males in whom a 
de  novo  gene mutation was responsible,  using the 
MLPA technique for molecular diagnosis of the dis-
ease in families with an affected male. In the present 
study population, de novo mutations were responsible 
for the disease in 16.7% of affected males. This is im-
portant information for providing correct genetic 
counseling. 
Material and Methods 
Patients 
The study included all consecutive males re-
ferred to the Genetic Diagnosis Unit of the San Cecilio 
University Hospital (Granada) by hospitals in the 
Andalusia region between February 2005 and May 
2013 for suspicion of DMD/BMD (ranging from iso-
lated increases in creatine kinase [CK] and transami-
nases to a full set of DMD/BMD symptoms), along 
with one or more female relatives (up to 3rd degree 
relationship). The study was performed in accordance 
with the ethical principles of the Helsinki Declaration, 
and all participants or their guardians signed their 
informed consent for the genetic studies. 
DNA isolation 
DNA was isolated in a QIAcube extractor (Qi-
agen Iberia, S.L. Madrid, Spain) from peripheral blood 
samples drawn by venipuncture into tubes containing 
ethylenediaminetetraacetic acid (EDTA) as anticoag-
ulant. DNA concentrations of samples were deter-
mined in a Jenway-Genove UV spectrophotometer 
(Jenway, Staffordshire, UK).  
MLPA analysis 
DMD  gene mutations were studied in the ex-
tracted DNA samples by MLPA assay in accordance 
with the manufacturer’s instructions (MRC Holland, 
Amsterdam, Holland). Briefly, DNA was denatural-
ized and hybridized for at least 12 h at 60 ºC with two 
probes: a probe containing oligonucleotides to ana-
lyze exons 1-10, 21-30, 41-50, and 61-70 (MIX 4); and a 
probe for exons 11-20, 31-40, 51-60, and 71-79 (MIX 5). 
Samples were treated with ligase for 15 min at 54 ºC, 
and the reaction was then stopped by incubation at 98 
ºC for 5 min. Finally, the amplified product was mixed 
with a specific SALSA®  product (oligonucleotide 
mixture) and underwent capillary electrophoresis in 
an ABI PRISM 310 genetic analyzer (Applied Biosys-
tems, Foster City, CA). Results were compared to 
those obtained for three control samples in the same 
run. Gene Mapper software version 4.0 (Applied Bi-
osystems, Foster City, CA) was used for the data 
analyses.  
Calculation of the number of copies and 
preparation of Ratio Peak Area (RPA) graphs 
Ratio peak areas (RPAs) were obtained for each 
run (MIX4 and MIX5) by dividing the area of the peak 
(A) corresponding to each exon by the sum of the ar-
eas  (∑As)  of  the  45  peaks  obtained  in  the  sample 
electropherogram. The RPA for each exon (As/∑As) 
was then divided by the corresponding peaks ob-
tained in the controls (Ac/∑As). All determinations 
for samples and controls were carried out in the same 
electrophoresis runs to yield comparable data. The 
RPA value is considered normal and reliable when it 
does not differ from the expected ratio by > 25%; the 
RPA is expected to be close to 1 in a healthy control. A 
sample is considered pathological in: a) males with 
one or more exons with RPA= 0 (deletion of corre-
sponding exon), b) males with one or more exons with Int. J. Med. Sci. 2014, Vol. 11 
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RPA =1.5-2.0 (duplication of corresponding exon), c) 
females with one or more exons with RPA ≈ 0.5 (dele-
tion carrier), and d) females with one or more exons 
with RPA=1.5-1.75 (duplication carrier). The diagno-
sis is more reliable if the detected mutation affects two 
or more consecutive exons, because a single exon de-
letion can be caused by a polymorphism in the gene 
sequence that is complementary to the probe used to 
detect the deletion.  
Results 
The study included 190 participants, 84 males 
aged between 1 and 52 yrs (the 52-yr-old had BMD) 
and 106 females aged between 1 and 72 yrs. A total of 
296 X chromosomes were analyzed. Out of the 84 
males, DMD gene mutations were detected by MLPA 
assay in 38 (45.2%) but not in 46 (54.8%). Among the 
46 males with no deletions or  duplications: 5 were 
relatives of the index case with no myopathy symp-
toms; 15 had clinical (positive Gowers’ sign, gait dis-
order), electromyographic, pathological, and/or bio-
chemical data compatible with DMD/BMD, implying 
the possible presence of some type of mutation un-
detectable by MLPA, e.g., small deletions, insertions, 
or point mutations; 3 patients were finally diagnosed 
by molecular analysis with Steinert disease (CTG tri-
plet determination by PCR amplification) and 1 with 
Landouzy Dejerine myopathy (Southern-blot of FSHD 
gene); and there were insufficient or missing clinical 
data in the remaining 22 patients (Table 1). Among the 
38 males with MLPA-detected DMD gene mutation, 
34 (89.5%) were diagnosed with exon deletions and 4 
(10.5%) with exon duplications. Out of the 34 males 
with exon deletions, 4 showed single exon deletions. 
The diagnosis of these patients was confirmed by us-
ing a single PCR (data not shown), given the possibil-
ity of a false positive result due to changes in the 
sample DNA sequence detected by the probe (SNPs, 
point mutations).  
 
 
 
Table 1. Summary of patient data on family history, clinical symptoms, biochemical data, electromyogram, and muscle biopsy compatible 
with Duchénnè/Becker muscular dystrophy. Information on patients with other myopathies and with incomplete/missing clinical data. 
Age 
(yrs) 
Family 
history 
Clinical 
symptoms 
Biochemical data  Electromyogram  Muscle biopsy  Clinical outcome 
15  -  Compatible 
with DMB 
Elevated CK and 
transaminases 
-  Partial absence of dystrophin  Currently in wheelchair; under me-
chanical ventilation program 
1  -  Compatible 
with DMD 
Elevated CK  -  Absence of dystrophin  Motor skill regression; continuing in 
rehabilitation program 
16  -  Compatible 
with DMD 
Elevated CK and 
transaminases 
-  Absence of dystrophin   
10  -  Compatible 
with DMD 
Elevated CK and 
transaminases 
Genetic analysis in external laboratory: presence of “codon stop” in DMD gene 
11  Yes   Compatible 
with DMD 
Elevated CK  -  Absence of dystrophin  - 
10  Yes   Compatible 
with DMD 
Elevated CK  -  Absence of dystrophin  - 
20  -  Compatible 
with DMD 
Elevated CK and 
transaminases 
Myopathy signs  Absence of dystrophin  Currently in wheelchair 
10  -  Compatible 
with DMD 
Elevated CK  -  -  Currently in wheelchair 
44  Yes   Compatible 
with DMB 
Elevated CK  Myopathy signs  Partial absence of dystrophin  Currently in rehabilitation program 
24  Yes   Compatible 
with DMB 
Elevated CK and 
transaminases 
Myopathy signs  Partial absence of dystrophin  No clinical outcome data 
22  Yes   Compatible 
with DMB 
Elevated CK and 
transaminases 
Myopathy signs  Partial absence of dystrophin  No clinical outcome data 
1.5  -  Compatible 
with DMD 
Elevated CK  Myopathy signs  Absence of dystrophin  Currently in rehabilitation program 
21  -  Compatible 
with DMD 
Elevated CK and 
transaminases 
-  Absence of dystrophin  Currently in wheelchair 
9  Yes  Compatible 
with DMB 
Elevated CK  -  Partial absence of dystrophin  No clinical outcome data 
3  -  Compatible 
with DMD 
Elevated CK and 
transaminases 
-  Pending result of muscle biopsy  Currently in rehabilitation program  
Patients with diagnosis of other myopathies  Waist dystrophy (Landouzy Dejerine myopathy): 1 patient Myotonic dystrophy (Steinert’s disease): 
3 patients 
Patients with incomplete/missing clinical data  22 patients referred for non-specific symptoms, including: muscle weakness, cramps, hyper-
transaminasemia, elevated CK, unclear family history, and psycho-motor retardation. 
CK, creatine kinase; DMD, Duchénnè muscular dystrophy; DMB, Becker muscular dystrophy 
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Out of the 106 female relatives (to 3rd  degree) 
studied, only 39 (36.8%) were mutation carriers; 35 of 
these (89.7%) carried exon deletions and 4 (10.3%) 
exon duplications. Table 2 displays the results of the 
24 studies of mother-son pairs. The mutation detected 
in the son was absent in the mother in four of these 
pairs (16.7%), indicating the presence of a de novo 
mutation. The study of the mother was not possible in 
14 of the 38 males diagnosed with gene deletion or 
duplication because the mother was dead (n=4) or not 
resident in Spain (n=2) or because the maternal sam-
ple was not delivered by the referring hospital. 
Figure 1 depicts the electropherograms and RPA 
graphs for a 7-yr-old male with DMD/BMD- 
compatible symptoms and family history and for his 
carrier mother.  
Figure 2 depicts the electropherograms and RPA 
graphs for a 3-yr-old male with DMD/BMD- 
compatible symptoms but no family history and for 
his non-carrier mother.  
 
 
 
Table 2. Data on the 24 son-mother pairs studied.  
  Affected exons in males  Affected exons in carrier mothers 
Age 
(yrs) 
Deletions  Duplications  Deletions  Duplications 
42  48-49  -  48-49  - 
12  3-52-promotor  -  3-52-promotor  - 
7  46-48  -  46-48  - 
19  12-19  -  12-19  - 
6  48-55  -  48-55  - 
5  48  -  48  - 
15  1-promotor  -  1-promotor  - 
15  45  -  45  - 
21  45-47  -  45-47  - 
4  45-47  -  Absent mutation  - 
19  3-7  -  3-7  - 
3  45-52  -  45-52  - 
1  3-7  -  3-7  - 
10  3-4  -  Absent mutation  - 
1  52  -  52  - 
1  45-54  -  45-54  - 
21  48  -  48  - 
1  8-16  -  Absent mutation  - 
15  61-77  -  61-77  - 
6  49-50  -  49-50  - 
5  -  2  Absent mutation  - 
2  3-17  -  3-17  - 
2  49-52  -  49-52  - 
8  8-44  -  8-44  - 
 
 
 
Figure 1. Electropherograms of male DMD patient with deletion of exons 8 to 44 and of his mother, a carrier of the same deletions. The figure only shows 
the electropherogram for the run in which exons 1-10, 21-30, 41-50, and 61-70 are analyzed. Each peak represents an exon of the dystrophin gene. Arrows 
indicate the absence of signals corresponding to deleted exons 8, 9, 10, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 41, 42, 43, and 44. The ratio peak area (RPA) 
graphs alongside the electropherogram show an RPA for deleted exons of 0 for the son and 0.5 for the mother.  Int. J. Med. Sci. 2014, Vol. 11 
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Figure 2. Electropherograms of male DMD patient with deletion of exons 8 to 10 and his non-deletion-carrying mother. The figure only shows the 
electropherogram for the run in which exons 1-10, 21-30, 41-50, and 61-70 are analyzed. Each peak represents an exon of the dystrophin gene. Arrows 
indicate the absence of signals corresponding to deleted exons 8, 9, and 10. The ratio peak area (RPA) graphs alongside the electropherograms show an 
RPA for deleted exons of 0 for the son and 1 for the mother. 
 
Discussion 
It has been known since 1987 that DMD/BMD is 
caused by mutations of the DMD gene, the largest 
known human gene (2.4 Mb and 79 exons) [20, 21]. 
The recently developed MLPA assay [14, 15] allows 
deletions and duplications to be detected in any of the 
79 exons of this gene. We used this method to carry 
out a genetic study of DMD/BMD disease in 84 males. 
DMD gene mutations were detected in 38 of them and 
a further 15 were diagnosed with DMD/BMD based 
on clinical, electromyographic, and muscle biopsy 
data.  
If we assume that the 15 males with 
DMD/BMD-compatible symptoms have mutations 
not detected by MLPA, it can be stated that the muta-
tions in the 53 males with DMD/BMD were deletions 
(64.1%) or duplications (7.5%) or undetected small 
deletions, insertions, or point mutations (28.3%). 
These data are in agreement with previously pub-
lished findings [5-7].  
In 1935, Haldane claimed that a third of 
DMD/BMD cases involved spontaneous dystrophin 
gene mutations [8]. Findings since that date have been 
controversial, with a similar frequency being reported 
by some authors [21] but a higher [22] or lower fre-
quency (around 20%) [23] by others. A sporadic mu-
tation was detected in 16.7% of the present series of 
DMD/BMD patients. However, given the small sam-
ple size of 24 son-mother pairs, further investigation is 
warranted in a larger number of cases. Three out the 
four de novo mutations in the present study were de-
letions, one in the distal region and two in the proxi-
mal region, and there was only one duplication, con-
sistent with suggestions that deletions are more fre-
quent in de novo mutations than in other mutations 
[24]. 
There have been reports of both somatic [25] and 
germinal [26, 27] mosaicism in patients with dystro-
phinopathies. Knowledge of the carrier or non-carrier 
status of a woman is vital for genetic counseling be-
cause of the risk of recurrence from germinal mosai-
cism, recently estimated as 4.3% [28]. The lack of an 
effective treatment for this disease makes its preven-
tion of paramount importance. In this context, prena-
tal diagnosis has offered women in DMD families the 
possibility of preventing the birth; however, as Hel-
derman-van den Enden et al. recently pointed out in a 
study in the Netherlands, families with de novo muta-
tions in the DMD gene cannot make use of prenatal 
diagnosis [29]. For this reason, it is essential not only 
to determine mutations in index cases but also to 
identify female carriers. 
Furthermore, although most female carriers do 
not have symptoms of muscular disease, it is now 
known that a significant percentage suffer from mus-Int. J. Med. Sci. 2014, Vol. 11 
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cle weakness and even dilated cardiomyopathy [30], 
and a five-yearly cardiac examination has been rec-
ommended by some authors [31]. There appears to be 
a wide consensus in favor of following up female car-
riers of DMD/BMD disease in order to rule out car-
diac disease. 
Although our results shed light on the propor-
tion of de novo mutations in an Andalusian popula-
tion, it is limited by the failure to include 14 of the 38 
mother-son pairs traced and by some incomplete or 
missing clinical data for the others. However, given 
the very low incidence of this disease (1:3500 live 
newborn males for DMD and 1:18000 for BMD), the 
sample size achieved can be considered a study 
strength.  
In conclusion, the MLPA assay is a sensitive, fast, 
and effective tool for diagnosing deletions and du-
plications of the dystrophin gene in affected males 
and carrier mothers. The assay offers a completely 
reliable diagnosis of the carrier or non-carrier status of 
the mother of a son with this disease, allowing ap-
propriate genetic counseling to be offered with no 
need for muscle biopsy in most individuals with 
DMD/BMD. 
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